American Veterinary Distributors Association Supports Human-Animal Bond Research and Education
WASHINGTON, D.C. (February 6, 2015) — The Human Animal Bond Research Initiative (HABRI) Foundation today announced that the American Veterinary Distributors Association (AVDA) has made a $5,000 donation to help gather, fund and share scientific research that demonstrates the human health benefits of pet ownership. "The industry leading companies that form the AVDA understand the importance of the human-animal bond and how it enhances both human and animal health," said HABRI Executive Director Steven Feldman. "The veterinary community plays a key role in the health of our communities and AVDA's support will help deliver that message."
"AVDA is proud to join the Human Animal Bond Research Initiative effort," said AVDA Executive Director Jackie King. "By supporting research and education on the benefits of the human-animal bond, AVDA can help bring the health benefits of pets to more people and more families." Click here to read the press release.
To learn more about HABRI visit their website, www.habri.org.
AVDA Co-Sponsors 3rd Annual "The Gathering" Reception at NAVC
Join AVDA for the 3rd Annual "The Gathering" reception at NAVC. Special thanks to our co-sponsors Animalytix and KC Corridor! Sunday January 18, 2015 from 5:00-6:30pm at Gaylord Palms. Click here to view the invitation.
AVDA 2015 Annual Conference Draft Schedule and Speakers Announced
AVDA is pleased to announce the draft schedule and speakers for the 2015 Annual Conference to be held at the Belmond Charleston Place Hotel in Charleston SC, April 26-28, 2015. Click here for the 2015 Annual Conference Draft Schedule.
Several changes have been made to the 2015 schedule due to the city location of this year's event. The Annual Scramble Golf Tournament has been moved to Monday afternoon to allow for travel to the Wild Dunes Links Course, approximately 30 minutes from the hotel. This Tom Fazio designed course has been consistently ranked in the top twenty-five courses in the United States since its inception in 1977. The Annual Meeting and Lunch have been moved to Tuesday afternoon and the AVDA No-Tie lounge will be held at the beautiful and historic Boone Hall Plantation on Tuesday evening.
Confirmed speakers include Steve McClatchey, Lynne Lancaster, Alan Beaulieu and Steve Gilliland. Additional information about these speakers can be found below. Details about the speaker topics and presentations will be sent out later this year and will be posted on the AVDA website. The promotional brochure for the event will be mailed to members in January 2015.
AVDA ITR Advisor Newsletter
AVDA is pleased to announce that AVDA has partnered with ITR Economics to provide the monthly ITR Advisor, a 4-page snapshot of the current economy, using leading indicators to tell subscribers where the economy is headed and what actions to take now. Written in a conversational tone, not heavy economic-speak, the ITR Advisor is a simple, quick, timely, and affordable way to stay informed about the state of the economy, with useful guidance and clear action points. This is another member benefit that we are providing to our members. This email newsletter will be sent to all principals and alternates at AVDA member companies.
Drug Quality and Security Act Resources
The FDA recently released a Guidance Document on how to exchange product tracing information (Transaction History, Transaction Information and Transaction Statement) under the Federal Drug Supply Chain Security Act (DSCSA).
Click here for resources and documents.
A link to the document that was issued on December 7, 2014 can be found HERE.
DEA Approves Making Tramadol a Schedule IV Controlled Substance
The Drug Enforcement Administration (DEA) recently published its decision to schedule tramadol as a Schedule IV controlled substance. The rule will become effective August 18 of this year. The DEA's action was fairly swift, having published its proposal to schedule tramadol just eight months ago. Upon conducting its eight-step analysis, the DEA found that relative to Schedule III drugs, tramadol has a low potential for abuse and limited physical dependence, and coupled with tramadol's medical legitimacy, DEA determined Schedule IV to be the most fitting for tramadol. Click here for more.
AVDA recently submitted public comments in regards to the DEA's Federal Register notice of proposed rulemaking: Schedules of Controlled Substances: Placement of Tramadol Into Schedule IV.
AVDA supports DEA's proposed rule designating Tramadol as a scheduled IV controlled substance because this action will enable distributors to operate with efficiency and consistency across the states along with requiring an increased level of due diligence and monitoring. Tramad l is an important drug in veterinary medicine and is supplied to veterinarians and animal health clinics by our distributor members. Tramadol is administered to dogs, cats and many non-domestic animals as an analgesic and as a pain reliever after surgical procedures. Click here to read the full document.
Legal Update: FTC Enforcement Actions Continue
At the September, 2013 Board meeting I advised you of recent activity of the Federal Trade Commission pertaining to the exchange of sensitive business information by and between competitors (Federal Trade Commission v. Bosley, No. 121-0184). While the information exchange was clearly inadvisable, the Commission's position was not based upon any allegations of harm to competition. Rather, the Commission used its authority under Section 5 of the FTC Act to find the Respondent violated the Act solely by exchanging the information and presuming such an exchange could lead to an adverse impact on competition.
The FTC continues to scrutinize the activities of competitors and trade associations. The Commission recently published proposed consent orders in two cases involving trade associations which are discussed below. Click here to read the full update.